Table 2 Effect of Endostar on plaque thickness and neovascularization

From: The Therapeuatic Effect of Endostar on Soft Carotid Plaque Neovascularization in Patients with Non-small Cell Lung Cancer

  

Before treatment

After treatment

N

T value

P value

Plaque thickness (mm)

Control

2.38 ± 0.49

2.41 ± 0.72

34

0.201

0.841

 

NP

2.42 ± 0.63

2.39 ± 0.71

48

0.219

0.827

 

ENP

2.41 ± 0.57

2.39 ± 0.62

43

0.156

0.877

EI (dB)

Control

7.67 ± 1.44

7.69 ± 1.33

34

0.060

0.953

 

NP

7.65 ± 1.25

7.59 ± 1.76

48

0.193

0.848

 

ENP

7.78 ± 1.56

6.23 ± 1.36

43

4.91

<0.01

  1. Note: Data are the mean ± standard deviation. NP = vinorelbine + cisplatin; ENP = Endostar + vinorelbine + cisplatin; EI = Enhanced intensity.
  2. There were no significant differences in plaque thickness and EI among the three groups at recruitment (P > 0.05 for all). There was no significant change in the EI of plaque in the controls or NP groups at 1 month after treatment (P > 0.05). While EI in the ENP group was significantly reduced at 1 month after treatment (P < 0.01) and significantly lower than that in the controls or NP groups at 1 month after treatment (P < 0.001 for both).
Back to article page